Author : Prasetyo Widhi Buwono, Hari Hendarto, Abdul Halim, Efriadi Ismail, Siti Chandra Wijananti, Mega Halida, Robby Herwindo, Corine, Abdul Haris, Femmi Nurul Akbar, Faisal Parlindungan, Andi Khomeini Takdir Haruni, Darwin Prenggono, Felix Sumampouw, Nicholas Carley Widjojoatmodjo, Jamaluddin Lukman, Ahmad Hidayat,

Abstract : Introduction: Hypercoagulability is a hallmark of coronavirus disease (COVID-19) complications, including Pulmonary Embolism and Multiple organ failure, which are the leading causes of mortality. Anticoagulant therapy is a hallmark therapy for COVID-19 patients with hypercoagulability. In this study, we used enoxaparin ovine as the anticoagulant. Methods: A retrospective cohort study was conducted among 24 patients with COVID-19 admitted to Wisma Atlet Kemayoran COVID-19 Emergency Hospital between April 2022 and October 2022. D-dimer levels were determined on an I-Chroma cs2100, and X-rays were taken with a Rotanode E7239X. Result: Analytics were calculated using SPSS ver. 21. P value were considered statistically significant at P < 0.05, and there was a correlation between the decreased D-dimer group and the targeted D-dimer group levels after enoxaparin ovine treatment. (P<0.00). Factors including vaccination (P=0.163) and comorbidity (P=0.259) did not affect enoxaparin prophylaxis. Conclusion: Enoxaparin ovine prophylaxis prevents clinical deterioration in covid-19 patients. Bleeding is expected in enoxaparin ovine prophylaxis therapy, as well as in other anticoagulant therapies. Although it has an effect in decreasing D-dimer levels, we could not conclude that it did not lack efficacy because the majority of the patients were not on an oxygen device.

Volume and Issue
Full Article Download